Profound Medical Corp. (PRN.TO) TSX
9.11
+0.11(+1.22%)
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.11
+0.11(+1.22%)
Currency In CAD
Address
2400 Skymark Avenue
Mississauga, ON L4W 5K5
Canada
Phone
647 476 1350
Sector
Healthcare
Industry
Medical - Devices
Employees
142
First IPO Date
July 10, 2018
| Name | Title | Pay | Year Born |
| Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer | 1.38M | 1955 |
| Thomas Tamberrino | Chief Commercial Officer | 529,048 | 1980 |
| Rashed Dewan | Chief Financial Officer | 653,727 | 1968 |
| Mathieu Burtnyk | President | 664,197 | 1982 |
| Levant Tinaz | Software Developer | 0 | N/A |
| Matthew Sobczyk | Assistant Corporate Controller | 0 | N/A |
| Stephen Kilmer | Investor Relations | 0 | N/A |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.